Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Silvia Martini1, Mariangela Figini2, Aurora Croce1

  • 1Molecular Pharmacology Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Cells
|October 7, 2020
PubMed

Insights

Combining selinexor with a TRAIL-R2xCD3 bispecific antibody enhances T-cell-mediated killing of triple-negative breast cancer (TNBC) cells. This potent combination therapy significantly increases tumor cell death and growth inhibition in TNBC.

Area of Science:

  • Immunotherapy
  • Oncology
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited treatment options.
  • Bispecific antibodies (BsAbs) redirect T cells to target cancer cells, showing promise in immunotherapy.
  • TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) targeted BsAbs have demonstrated efficacy against TNBC.

Purpose of the Study:

  • To investigate the potential of selinexor, a selective inhibitor of nuclear export (SINE), to enhance the antitumor activity of a TRAIL-R2xCD3 bispecific antibody.
  • To evaluate the combined efficacy of selinexor and the TRAIL-R2xCD3 BsAb in TNBC treatment.

Main Methods:

  • In vitro combination experiments were conducted using TNBC cell lines.
  • Cell growth inhibition was assessed in response to single-agent and combination treatments.
  • Apoptosis rates were quantified in treated TNBC cells.

Main Results:

  • Selinexor treatment potentiated the antitumor activity of the TRAIL-R2xCD3 BsAb, resulting in greater growth inhibition than additive effects.
  • The combination therapy significantly increased the apoptosis rate in TNBC cells compared to either agent alone.
  • TNBC cells expressing TRAIL-R2 were effectively targeted by the BsAb, with enhanced killing in the presence of selinexor.

Conclusions:

  • The combination of selinexor and the TRAIL-R2xCD3 BsAb represents a promising therapeutic strategy for TNBC.
  • This combination therapy demonstrates enhanced antitumor activity through increased T-cell-mediated cytotoxicity and apoptosis induction.
  • Further investigation is warranted to explore this combination as a viable treatment option for patients with triple-negative breast cancer.